Alec Van Gelder: Novo Nordisk Opens Global Patient Advocacy Role for Haemoglobinopathies
Alec Van Gelder, Vice President of Corporate Affairs, Rare Disease at Novo Nordisk, shared a post on LinkedIn:
“We’re Hiring: Associate Director, Patient Advocacy – Haemoglobinopathies at Novo Nordisk Rare Disease.
With recent progress in Sickle Cell Disease marking a pivotal moment for the haemoglobinopathy community, there has never been a more important time to help shape what comes next for patients.
We are looking for a passionate and experienced Associate Director of Patient Advocacy to partner with the haemoglobinopathies community and lead our global patient advocacy work — ensuring that the voices of those living with conditions like SCD and thalassemia sit at the very heart of Novo Nordisk’s access strategy and external engagement.
If you have a passion for improving the lives of people living with sickle cell disease and thalassemia, we would love to hear from you.
Apply now and be part of the story we are writing together with the haemoglobinopathy community.”
Stay updated with Hemostasis Today.
-
Aug 19, 2026, 09:12Charlie Berman: Infections Following Mechanical Thrombectomy for Acute Stroke
-
Aug 19, 2026, 08:39Choosing the Right P2Y12 Inhibitor After PCI – JAMA Cardiology
-
Aug 19, 2026, 08:05Charles Cohen: Why Women Wait Years Longer for a Bleeding Disorder Diagnosis
-
Aug 19, 2026, 07:42Chukwuemeka Amarachi: Thalassemia – Types, Diagnosis and Management
-
Aug 19, 2026, 07:15Ajay Kumar: Real-World Outcomes of Plasma Exchange in NMOSD
-
Aug 19, 2026, 07:02Amer Zeidan: Managing Anemia in Lower-Risk MDS
-
Aug 19, 2026, 06:24GT Connect – Connecting the GT Community – Glanzmann’s Research Foundation
-
Aug 19, 2026, 01:43Elvira Grandone: Cancer and Thrombosis in Women – Where Do We Stand?
-
Aug 19, 2026, 01:37Ifeanyichukwu Ifechidere: Coagulation Knowledge – A Core Skill in Internal Medicine